Grail
Grail, AstraZeneca Partner on Companion Dx for Oncology Drugs
The partners will focus first on developing companion diagnostics to identify cancer patients with high-risk, early-stage disease.
Grail, Veterans Affairs to Evaluate Galleri Cancer Early Detection Test
Grail will make Galleri available to 10,000 veterans, who may then participate in the company's observational REFLECTION study.
Guardant Health Files Motions to Dismiss, Change Venue in Illumina Patent Lawsuit
Guardant claimed that a patent lawsuit filed against it by Illumina in March was filed in an inappropriate district court and is a “brazen attempt” to stifle competition.
Intermountain Healthcare Rolling Out Galleri Multi-Cancer Early Detection Test in Pilot Program
Premium
The test is first available to employees over age 50 covered under Intermountain's SelectHealth, but the health system has a bigger five-year plan.
Point32Health to Offer Grail Cancer Early Detection Test Under Pilot Program
The health plan provider will make testing available to its own employees, followed by its approximately 2.2 million commercial members.
Apr 15, 2021
Jan 11, 2021
Sep 21, 2020
Illumina to Acquire Grail for $8B in Cash and Stock
Apr 29, 2020
Oct 1, 2019
ESMO 2019 Precision Oncology Highlights
May 10, 2019
Apr 1, 2019